Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
The following is a brief description of each matter voted upon at
the Annual Meeting, as well as the number of votes cast for or
against each matter and the number of abstentions and broker
non-votes with respect to each matter. Of the 43,241,281 shares
of the Companys common stock entitled to vote at the Annual
Meeting, 38,927,533 shares of common stock, or 90.02%, of the
total eligible votes to be cast, were represented at the Annual
Meeting in person or by proxy, constituting a quorum. A more
complete description of each matter is set forth in the Companys
definitive proxy statement for the Annual Meeting, which was
filed with the Securities and Exchange Commission on March31,
2017.
Proposal 1: Election of Directors
The stockholders elected L. Patrick Gage, Edward M. Kaye and
Wendell Wierenga as ClassI Directors, each to serve for a
three-year term and until their successors are duly elected and
qualified. The voting for each director was as follows:
|
Name |
For |
Withheld |
BrokerNon-Vote |
|||||||||
|
L. Patrick Gage |
31,235,018 | 143,950 | 7,548,565 | |||||||||
|
Edward M. Kaye |
30,838,654 | 540,314 | 7,548,565 | |||||||||
|
Wendell Wierenga |
31,162,950 | 216,018 | 7,548,565 |
Proposal 2: Ratification of Independent Registered
Public Accounting Firm
The stockholders ratified the selection by the Audit Committee of
the Board of Directors of PricewaterhouseCoopers LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017. The votes were as follows:
|
For |
Against |
Abstain |
||
|
38,714,180 |
172,993 | 40,360 |
Proposal 3: Approval of an amendment to the Amended
and Restated 2004 Equity Incentive Plan to increase the number of
authorized shares reserved for issuance under the Amended and
Restated 2004 Equity Incentive Plan.
The stockholders approved the Amended and Restated 2004 Equity
Incentive Plan to increase the number of authorized shares
reserved for issuance under the Amended and Restated 2004 Equity
Incentive Plan by 3,900,000 shares. The votes were as follows:
|
For |
Against |
Abstain |
Broker Non-Vote |
|||
|
19,689,832 |
7,562,216 | 4,126,920 | 7,548,565 |
Proposal 4: Advisory Vote on Executive
Compensation
The stockholders approved, on an advisory basis, the compensation
of the named executive officers, as disclosed in the Companys
Proxy Statement for the 2017 Annual Meeting of Shareholders. The
votes were as follows:
|
For |
Against |
Abstain |
Broker Non-Vote |
|||
|
31,058,363 |
282,247 | 38,358 | 7,548,565 |
Proposal 5: Advisory Vote on Frequency of Say On
Pay
The stockholders voted, on an advisory basis, that future
advisory votes on executive compensation should be submitted to
the stockholders every year. The votes were as follows:
|
Every three years |
Every two years |
Every year |
Abstain from voting |
Broker Non-Vote |
||||
|
7,547,820 |
78,240 | 23,732,163 | 20,745 | 7,548,565 |
About Cytokinetics, Incorporated (NASDAQ:CYTK)
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure. Cytokinetics, Incorporated (NASDAQ:CYTK) Recent Trading Information
Cytokinetics, Incorporated (NASDAQ:CYTK) closed its last trading session down -0.05 at 14.20 with 533,867 shares trading hands.